The eight-step workflow.

The sharpest unit is not “a device.” It is “de-risked partner readiness.”

ImmunoShield should likely monetize in stages: feasibility package → platform license → per-device/per-dose economics → strategic option/acquisition. This matches their stated desire to raise and partner against de-risked milestones rather than promise alone.

Bottom line: the easiest unit to sell is a paid feasibility study; the most valuable unit is a platform license + milestones; the riskiest unit is a pure per-device fee unless it is bundled into partner development first.

Assumption: pressure-test against $500K near-term, $5M seed/Series A validation, and $25M strategic value creation. ImmunoShield’s own deck frames the market as $1.5B allogeneic cell therapies, $18.3B cell therapies, and $37.6B global T1D, with a current ask of $500K pre-seed and a longer strategic roadmap toward initial investment, milestone licensing, and acquisition.

If the addressable allogeneic cell therapy market is $1.5B, then:

• $500K revenue = 0.03% of market
• $5M revenue = 0.33%
• $25M revenue = 1.7%

Those shares are not the constraint.

The real constraint is account adoption. There may only be a small number of serious near-term buyers: Vertex/ViaCyte, Lilly/Sigilon, Sernova, Sana, plus a handful of other cell therapy developers and CDMO/manufacturing partners. Vertex acquired ViaCyte for $320M; Lilly acquired Sigilon in a deal worth up to $309.6M; AstraZeneca acquired EsoBiotec for up to $1B, including $425M upfront and $575M in milestones. (Vertex Pharmaceuticals)

So the better question is not “What market share?” It is:

Can ImmunoShield get 1–3 serious strategic partners to pay for de-risking?

That is plausible.

Good unit: $75K–$150K per partner study.

This is the lowest-friction sale. It lets Vertex-like, Lilly-like, Sernova-like, or Sana-like teams test ImmunoShield without committing to a platform license.

Problem: to reach $5M, they would need roughly 33–67 studies, which is implausible in such a concentrated market.

Redefine if needed: Make it a paid partner-readiness sprint: $150K–$250K for cell compatibility, manufacturability, retrievability, and immune-protection data.

Good unit: $500K–$1.5M.

This fits the company’s stage: partner engagement, feasibility studies, platform data package, and IND-enabling readiness.

Plausibility: 1 package funds the current ask; 3–5 packages could create meaningful validation.

Best buyer: biotech or pharma cell sponsor.

Good unit: $1M–$3M upfront, plus milestones.

Plausible after large-animal or compelling partner-specific data.

Problem: too expensive before the partner believes ImmunoShield reduces their own program risk.

Redefine if needed: Start with an option-to-license: smaller upfront, defined option window, partner-funded studies, pre-negotiated milestone path.

Good unit: $5M–$25M per development/regulatory milestone.

This aligns with biotech deal precedent. The AstraZeneca/EsoBiotec deal included $575M in contingent development/regulatory milestones; Lilly/Sigilon included a large CVR structure tied to milestones. (AstraZeneca)

Problem: milestones only matter after a license or co-development deal exists.

Redefine if needed: Use micro-milestones first: $250K–$1M for completion of partner-specific feasibility, animal study readouts, regulatory package readiness.

Good unit later: $1K–$10K per device or dose equivalent.

Problem: no one wants to negotiate per-device economics before clinical dose, manufacturing process, and pricing are clear.

Redefine if needed: Use per-program access fee + later per-dose royalty. That preserves upside without forcing early precision.

The most plausible sequence:

1. Paid feasibility sprint

$150K–$250K per partner.

1. Co-development package

$500K–$1.5M per partner program.

1. Option-to-license

$1M–$3M upfront.

1. Milestone-based license

$5M–$25M+ per milestone.

1. Per-dose/device royalty

Only after clinical and manufacturing economics become visible.

Do not lead with “pay us per device.” Lead with “pay us to reduce your program risk.”

For ImmunoShield, the unit should evolve as trust increases:

Study → Package → Option → License → Milestone → Per-dose economics

That matches their own framing: “raise against de-risked milestones rather than promise alone.”

Best fit: the unit should make ImmunoShield look like platform infrastructure, not a one-off service vendor.

Co-development package → option-to-license → platform license.

That sequence advances the strategy because it sells what ImmunoShield actually wants to be:

the layer that makes partner cell therapies safer, scalable, retrievable, and investable.

Verdict: Advances, but only if framed correctly.

It supports partner readiness by letting a cell sponsor test compatibility, manufacturability, and early performance.

But if sold as “we’ll run a study for you,” it retreats into CRO-like work.

Better definition: Partner-readiness sprint with pre-negotiated option rights.

Verdict: Strong advance.

This is the cleanest strategic fit.

It proves ImmunoShield can integrate with external cell sources, which is central to the “enabling layer” strategy. It also builds evidence around:

• Protection
• Retrievability
• Manufacturing fit
• Partner readiness

This matches the deck’s positioning: “an enabling player, not another full-stack cell bet.”

Verdict: Strong advance.

A platform license tells the market:

ImmunoShield is not selling experiments. It is selling infrastructure.

This reinforces:

• Manufacturing fit
• Partner readiness
• Acquisition value
• Long-term platform defensibility

Best once they have partner-specific data.

Verdict: Advances, but later.

Milestones support acquisition value because they show pharma is willing to pay as risk comes down.

But milestones are not the first unit. They are the reward for successful platform adoption.

Best tied to:

• IND-enabling data
• FDA meeting outcomes
• partner product nomination
• first large-animal success
• clinical entry

Verdict: Potential retreat.

A per-device fee can monetize protection and retrievability, but it risks defining ImmunoShield as a device/component vendor.

That would undercut the broader strategy.

Better definition: Per-device fee should be a downstream royalty inside a broader platform license, not the headline unit.

Lead with:

“Partner-readiness co-development package with option-to-license.”

This advances the platform position because it sells the full bundle:

protection + retrievability + manufacturing fit + partner readiness + future acquisition value.

Core answer: adoption is not effortless. Even if ImmunoShield is attractive, a partner must change the _product architecture_ of its cell therapy.

The biggest friction is not “Can this work?”

It is:

“Can we adopt this without breaking our development plan?”

For Vertex, Lilly/Sigilon, Sernova, Sana, or similar players, ImmunoShield may improve protection, retrievability, manufacturing fit, immune tolerance, and patient breadth — but it also risks forcing them to revalidate a core product architecture. That is expensive, slow, and politically sensitive.

Feasibility study: low–moderate friction Easy because it does not force commitment.

Co-development package: moderate friction Useful, but partner must share cells, data, process assumptions, and strategic intent.

Platform license: high friction Now ImmunoShield becomes part of the product definition.

Per-device economics: high friction if premature Partners will resist pricing a unit before dose, workflow, reimbursement, and manufacturing cost are known.

Acquisition / option: painful but strategically clean High commitment, but removes internal build-vs-buy ambiguity.

Do not ask partners to abandon their platform early.

Offer:

“Let us test whether ImmunoShield improves your cells without requiring you to redesign your program yet.”

This lowers emotional and technical resistance.

Make the first unit a structured sprint:

• cell compatibility
• encapsulation feasibility
• function after encapsulation
• immune-protection signal
• retrievability rationale
• CMC integration memo
• regulatory implications memo

This turns adoption from a platform bet into a controlled experiment.

Partners will worry about combination-product complexity.

Give them:

• FDA interaction plan
• pre-IND / INTERACT logic
• risk register
• precedent map
• assay-development plan

ImmunoShield’s deck already emphasizes automated injection molding and manufacturing fit. That should be turned into a buyer-facing artifact:

“Here is exactly where we plug into your process.”

Use an option-to-license structure:

• small upfront
• defined study scope
• option window
• pre-negotiated license terms
• milestone-based conversion

This reduces the fear of being locked in too early.

Instead of selling:

“Adopt our platform.”

Sell:

“A partner-readiness package that tells you whether your cells become safer, more scalable, retrievable, and more investable with ImmunoShield.”

That advances the platform position while reducing switching friction.

Core read: ImmunoShield’s first buyer is unlikely to be “the company.” It is a cross-functional buying committee where external innovation opens the door, translational/CMC validates fit, cell-therapy leadership sponsors, legal signs, and regulatory owns the fear.

Usually the person closest to the program bottleneck:

• Translational engineer: sees encapsulation, oxygen transport, retrievability, or immune rejection issues.
• CMC lead: sees scalability, reproducibility, and manufacturing-fit risk.
• Cell therapy program lead: sees eligibility and immunosuppression limiting the commercial case.
• External innovation scout: sees whitespace: “cells are validated, immune management remains open.”

The recommender is likely a technical-commercial bridge person:

• External innovation director
• Translational engineering lead
• CMC/process development lead
• Scientific advisor/KOL
• Diabetes program champion

The deck’s customer discovery quotes point directly to these people: CMC lead, external innovation director, and translational engineer at large pharma.

For a paid feasibility study or partner-readiness sprint:

• Large pharma: external innovation budget, BD innovation fund, or program team budget.
• Biotech: CEO/CSO/CFO, often with board awareness.
• CMC team: technical operations budget if framed as manufacturing/process risk reduction.
• Translational team: program budget if tied to preclinical de-risking.

Usually not the technical champion.

• Legal
• Procurement
• BD/contracts
• Tech transfer/IP counsel if rights are involved

If cells or confidential process data are shared, expect CDA/MTA terms before a broader feasibility or option agreement.

Depends on partner type:

• Large pharma / biotech: program team or cell-process development group.
• CDMO: may provide process context, not necessarily proprietary therapeutic cells.
• Academic/KOL collaborator: may provide model cells for noncompetitive proof.

This is a friction point: once a partner provides cells, ImmunoShield moves from “interesting platform” to “inside the product architecture.”

Likely split:

• ImmunoShield runs encapsulation/device feasibility.
• Partner runs or observes cell-function assays.
• CRO/academic partner may run animal studies.
• QA/CMC reviews reproducibility, release testing, and documentation.

ImmunoShield’s deck already frames next steps around preclinical studies, partner engagement, feasibility studies, and regulatory readiness.

This is crucial.

For standalone enabling technology: ImmunoShield owns more.

For partner-integrated cell therapy: the cell therapy sponsor ultimately owns IND and product risk.

That means regulatory must be involved early. Otherwise the buyer may like the science but reject adoption because it complicates the package.

Different failure modes trigger different critics:

• Poor cell function: cell biology / translational team.
• Poor oxygen transport or fibrosis: preclinical / device team.
• Manufacturing mismatch: CMC and technical ops.
• Assay ambiguity: QA/QC.
• Regulatory uncertainty: regulatory affairs.
• Slow partner process: BD and program leadership.
• Unclear economics: portfolio strategy / finance.

The best first champion is the translational engineering or CMC leader who already believes immune rejection and manufacturability are blocking adoption.

They have the pain, vocabulary, and credibility to pull in the rest of the buying committee.

Do not sell one message to everyone.

Use a role-specific wedge:

• External innovation: “Whitespace and strategic option value.”
• Program lead: “Broader eligible population.”
• Translational engineering: “Protection, retrievability, oxygen transport.”
• CMC: “Manufacturing fit and scalable device format.”
• Regulatory: “Early clarity before the platform becomes locked in.”
• BD/legal: “Option-to-license with milestone-based risk reduction.”

Core test: ImmunoShield adoption only works when the partner’s pain is bigger than the disruption of changing the product architecture.

They will switch because immunosuppression narrows the eligible T1D patient pool and weakens the commercial case, which ImmunoShield relieves by protecting allogeneic cells through macroencapsulation and later immune tolerance, and switching cost device integration + preclinical validation + regulatory complexity is less than the relief because expanding eligibility from ~300K to a much broader 1.8M U.S. T1D population changes the product’s market potential.

Strength: Strong. Weak blank: Must prove the device does not compromise cell function or create surgical burden.

They will switch because their internal device may not solve fibrosis, oxygen transport, retrievability, manufacturing fit, and indirect immune rejection well enough, which ImmunoShield relieves by using a spiral macroencapsulation geometry designed for oxygen transport, retrievability, and scalable injection molding, and switching cost revalidating device format and CMC assumptions is less than the relief because a better product format could make their cells more partnerable and fundable.

Strength: Strong if the partner lacks a mature device. Weak blank: Harder if the biotech’s identity is already tied to its own device.

They will switch because immune management remains an unresolved whitespace even as cell therapies become clinically credible, which ImmunoShield relieves by offering an enabling platform that can be tested through feasibility work before full commitment, and switching cost small feasibility funding + internal champion time is less than the relief because the option value of finding a partner-ready immune-protection layer is high relative to the cost of exploration.

Strength: Very strong for opening doors. Weak blank: Needs a clear next step after feasibility, or it becomes “interesting science” with no adoption path.

They will switch because current encapsulation approaches may be hard to scale, reproduce, retrieve, or integrate into advanced cell manufacturing, which ImmunoShield relieves by hydrogel injection molding designed for reproducible, scalable, automated manufacturing fit, and switching cost process development, QA/QC assay work, sterility validation, and release-spec redesign is less than the relief because manufacturing fit is a gating requirement for any commercial allogeneic product.

Strength: Strong if CMC owns the pain. Weak blank: ImmunoShield must make the integration map concrete.

They will switch because hypoimmune gene editing can introduce product-performance, DNA-mutation, tumorigenicity, and autoimmunity risks, which ImmunoShield relieves by externalizing immune protection into a retrievable device plus local immune-tolerance strategy, and switching cost new preclinical models, device testing, and combination-product questions is less than the relief because a retrievable, non-genetic protection layer may reduce irreversible safety concerns while preserving the partner’s cell source.

Strength: Moderate to strong. Weak blank: Must avoid overstating that ImmunoShield fully replaces gene editing; it may complement it.

They will switch because Treg approaches may be costly, hard to scale, clinically uncertain, and non-antigen-specific, which ImmunoShield relieves by pairing macroencapsulation with pregnancy-inspired, local immune tolerance, and switching cost mechanism-of-action validation + efficacy studies + regulatory explanation is less than the relief because local tolerance could be more targeted and more product-compatible than systemic or separate immune-cell therapy.

Strength: Medium. Weak blank: The immune-tolerance program still needs more proof; this is a future-facing hypothesis.

They will switch because unprotected allogeneic cells face direct immune rejection, limited durability, and narrow patient eligibility, which ImmunoShield relieves by physically separating therapeutic cells from immune attack while maintaining cell function and enabling retrieval, and switching cost device implantation workflow + product redesign + CMC/regulatory updates is less than the relief because without immune protection, the product may remain commercially constrained or clinically unsuitable for broad T1D use.

Strength: Strong if the partner’s product depends on broad eligibility. Weak blank: Surgical workflow must be acceptable.

Large pharma or diabetes-focused biotech will switch because immune suppression and weak product format cap the eligible market, which ImmunoShield relieves through retrievable, scalable macroencapsulation and future immune tolerance; the switching cost is meaningful but acceptable because the reward is a broader, safer, more partner-ready allogeneic cell therapy product.

Pure immune-tolerance replacement for Treg or gene-editing strategies.

That may become powerful later, but today the stronger adoption wedge is:

“Let us make your existing cells more protected, retrievable, scalable, and partner-ready.”

Core answer: ImmunoShield should not tolerate classic SaaS-style CAC. In a partner-first biotech model, the relevant metric is cost per qualified partner conversation, then cost per paid feasibility / co-development conversion.

A qualified partner conversation means:

A named decision-maker or technical champion at a relevant pharma, biotech, CDMO, or manufacturing group agrees to discuss a concrete ImmunoShield use case involving cell source, device fit, CMC, immune protection, regulatory path, or partnership structure.

BIO 2026’s Premier Access includes BIO Partnering, education, networking, lunch, exhibition, company presentations, and Startup Stadium; BIO also states that partnering requires Premier Access or exhibitor partnering access. (BIO International Convention 2026) (BIO International Convention 2026) BIO exhibit space is listed at roughly $50–$54 per square foot, with a 10x10 booth package including five booth staff registrations. (Asp Events) Cell & Gene Meeting on the Mesa includes 1:1 partnering with registration, and a 2025 event listing showed costs from $650–$4,150. (Cell & Gene Meeting on the Mesa) (Phoenix Bioscience Core) ARMI/BioFabUSA is especially relevant because BioFabUSA is a public-private partnership with more than 170 members, and its project calls focus on ecosystem growth and impact. (ARMI) (ARMI)

Likely cost per qualified conversation: $7,500–$25,000

Large pharma is expensive because access is gated. The best channels are conference partnering, external innovation teams, KOLs, scientific advisors, and warm introductions. A single BIO or Meeting on the Mesa trip can be worth it if it produces 3–6 serious meetings.

CAC ceiling: $75K–$150K per paid feasibility / co-development conversion

Why: if the first commercial unit is a $150K–$250K partner-readiness sprint, CAC above ~$75K starts to look bad. If the target is a $500K–$1.5M co-development package, CAC up to ~$150K can still work.

Likely cost per qualified conversation: $3,000–$12,000

Smaller teams are easier to reach, especially through scientific advisors, T1D networks, publications, and shared KOLs. The conversation quality may be higher because they feel the immune-rejection and product-format pain directly.

CAC ceiling: $50K–$100K per paid conversion

This segment is promising, but many diabetes biotechs may be capital constrained. Keep first ask small and concrete.

Likely cost per qualified conversation: $2,500–$10,000

This is likely the cheapest high-quality pharma entry point. External innovation teams are paid to look for platform options. They may not own budget, but they can sponsor internal circulation.

CAC ceiling: $40K–$75K per qualified opportunity

The ceiling is lower because external innovation interest alone is not revenue. The goal is conversion into a program owner or technical champion.

Likely cost per qualified conversation: $4,000–$15,000

CMC teams are harder to access through investor-style conferences but more accessible through ARMI/BioFabUSA, CDMO networks, manufacturing consortia, and technical publications. ARMI/BioFabUSA’s manufacturing focus and member ecosystem make this channel unusually important. (ARMI)

CAC ceiling: $75K–$125K per paid technical package

This can support a higher ceiling if the offer is framed as CMC risk reduction, process integration, or manufacturability validation.

Likely cost per qualified conversation: $2,000–$8,000

These are best reached through papers, posters, advisors, scientific conferences, and peer-to-peer intros. ImmunoShield’s deck already includes customer-discovery quotes from a CMC lead, external innovation director, and translational engineer, suggesting these conversations are reachable and relevant.

CAC ceiling: $40K–$80K per paid feasibility conversion

This is a strong early champion segment, but they usually need to pull in program leadership before real money moves.

Assume these first paid units:

Rule of thumb: For early ImmunoShield, CAC should stay below 20–30% of the first paid unit, unless the conversation has clear path to strategic option, milestone economics, or acquisition value.

For the partner-first model, I would set three ceilings:

Qualified partner conversation: ≤$10K average

Above this, they are probably buying broad awareness instead of targeted access.

Qualified opportunity with a named internal sponsor: ≤$50K

Above this, the channel must show unusually high probability of paid feasibility or strategic partnership.

Paid feasibility / co-development conversion: ≤$100K–$150K

Above this, the first commercial unit needs to be redefined upward from “feasibility” to “co-development package” or “option-to-license.”

• Warm intros through Jessica Weaver, Holger Russ, Patti DuBois, Randy Vane, ARMI, BioFabUSA, ASU Skysong, and diabetes KOLs.
• Publication/poster-driven outreach to scientists already working on beta-cell replacement, encapsulation, oxygen transport, and immune tolerance.
• ARMI/BioFabUSA manufacturing and project-call relationships.
• Meeting on the Mesa-style partnering, because 1:1 partnering is built into the event model. (Cell & Gene Meeting on the Mesa)

• BIO and major conferences: valuable if pre-booked around target accounts, not as booth-driven awareness.
• Broad exhibit booths: risky unless subsidized or bundled with Startup Stadium / investor / strategic meetings.

ImmunoShield should aim for:

• $3K–$10K per qualified partner conversation
• $20K–$50K per serious opportunity
• $75K–$125K per paid feasibility or co-development conversion

If average paid conversion CAC exceeds $150K, the current partner-first model starts to break unless the first paid unit is at least $750K–$1.5M.

The cheapest conversation is not the goal. The goal is the cheapest conversation that reaches someone who can change a cell-therapy development plan.

For ImmunoShield, the winning motion is:

Warm technical credibility → targeted partner conversation → paid partner-readiness sprint → co-development / option-to-license.

Core test: if ImmunoShield needs more than 1–3 meaningful partner events per year, the model starts to stretch. If it needs 10+ platform licenses per year, it is implausible for a preclinical cell-therapy enabling platform.

Given:

• R = required annual revenue
• P = price per unit
• S = addressable partner count
• M = maximum plausible share of partners captured

Then:

Accessible partners = S × M
Required units = R ÷ P
Required annual units per accessible partner = R ÷ P ÷ (S × M)

Verdict thresholds:

• Feasible: ≤0.25 units / partner / year

Meaning one purchase every 4 years per accessible partner.

• Stretched: 0.25–1.0 units / partner / year

Meaning every accessible partner must buy roughly every 1–4 years.

• Implausible: >1.0 units / partner / year

Meaning each accessible partner must buy more than once per year.

For a preclinical allogeneic cell-therapy platform, the realistic addressable partner set is not huge.

A reasonable working assumption:

• S = 20–40 credible partners
• M = 10–25% plausible capture
• Accessible partners = 2–10

This includes likely strategic categories: Vertex/ViaCyte, Lilly/Sigilon, Sernova, Sana, diabetes-focused biotechs, broader allogeneic cell-therapy players, and select CDMO/manufacturing partners.

ImmunoShield’s own deck frames the company as partner-first, with platform data, partner engagement, financing, regulatory meetings, and acquisition as the path from high-risk to approved product.

At $100K each, feasibility studies work as door-openers, not as a revenue model.

To hit $5M, ImmunoShield would need 50 feasibility studies/year. That is unrealistic in a concentrated preclinical cell-therapy partner market.

Verdict: feasible for learning, implausible for scale.

At $500K each, one co-development package can cover the current pre-seed ask. But hitting $5M would require 10 packages/year.

That is too many unless the unit is broadened or bundled into a larger strategic program.

Verdict: feasible near-term; stretched as annual revenue engine.

At $2M upfront, ImmunoShield needs only 2–3 licenses to approach $5M.

That is more realistic than 50 feasibility studies, but still difficult for a preclinical platform unless large-animal data, CMC clarity, and regulatory logic are compelling.

Verdict: stretched but plausible after de-risking.

Large pharma does not need dozens of preclinical platform deals to create value. It needs one or two strategically important options.

Recent deal behavior supports this pattern: AstraZeneca agreed to acquire EsoBiotec for up to $1B, including $425M upfront and $575M in milestones, and Lilly’s Ascidian license was valued up to $1.9B with upfront, milestones, and royalties. (Reuters)

Verdict: feasible if ImmunoShield becomes strategically necessary.

Best unit:

One co-development package or 3–5 paid partner-readiness sprints.

Feasible.

Best unit:

2–3 platform licenses, or one meaningful option-to-license plus feasibility revenue.

Stretched but plausible.

Best unit:

Strategic option, milestone-bearing platform license, or acquisition path.

Implausible through feasibility studies or per-device fees. Plausible only through strategic pharma deal architecture.

If the math fails, do not lower price and chase more partners.

Redefine the unit upward:

“$100K feasibility study”

“$750K partner-readiness co-development package with option-to-license.”

Includes:

• partner cell compatibility
• macroencapsulation performance
• manufacturability assessment
• immune-protection data
• CMC integration memo
• regulatory pathway memo
• pre-negotiated option rights

This reduces adoption friction because the partner is not “buying ImmunoShield.” They are buying a controlled answer to:

“Does ImmunoShield make our cell therapy safer, scalable, retrievable, and more partner-ready?”

Feasible: $500K–$1M via co-development / partner-readiness packages. Stretched: $5M via 2–3 platform licenses or one strategic option. Implausible: $5M+ through small feasibility studies or per-device fees alone.

The business model should not depend on volume. It should depend on one or two partners believing ImmunoShield changes the fate of their cell-therapy program.

Best answer: the smallest credible expansion is not “all cell therapy.” It is:

Endocrine and metabolic cell therapies where therapeutic cells must survive long-term, secrete a biologic payload, and avoid chronic systemic immunosuppression.

That stays close to ImmunoShield’s proof base: T1D, insulin-secreting cells, macroencapsulation, retrievability, oxygen transport, immune protection, and manufacturing fit.

“Protected therapeutic-cell factories for endocrine and metabolic disease.”

This is broader than T1D, but still disciplined.

It preserves the core platform claims:

• Protection
• Retrievability
• Manufacturing fit
• Durable therapeutic output
• Reduced / eliminated immune suppression
• Partner-ready product format

They need to prove the platform works beyond one cell source.

Evidence needed:

• multiple cell types survive encapsulation
• function is maintained after encapsulation
• oxygen / nutrient transport remains adequate
• device geometry does not need full reinvention for every cell type

For endocrine or biologic-factory uses, the core question is:

Does the device preserve clinically meaningful output over time?

Evidence needed:

• sustained secretion curves
• response to physiological demand, if relevant
• survival under immune challenge
• function after retrieval

T1D may not generalize if another cell type needs a different implantation environment.

Evidence needed:

• site-specific viability
• fibrosis response
• retrievability
• surgical workflow fit

The platform claim depends on manufacturing fit.

Evidence needed:

• reproducible encapsulation across cell types
• QC/release assays
• sterility and stability logic
• process compatibility with partner cell manufacturing

Do not expand because the platform “could” apply.

Expand only when a partner says:

“If you can show this works with our cells, it changes our program.”

That is the real scope-expansion trigger.

Do not expand into broader allogeneic cell therapy until ImmunoShield can show:

At least two distinct therapeutic cell types can be encapsulated, remain functional, resist immune attack, and fit a believable CMC/regulatory path.

Until then, “platform” should mean:

repeatable within adjacent secretory-cell use cases

not:

works for everything.

T1D should remain the proof beachhead.

But the investable expansion story should be:

T1D proves the platform; adjacent endocrine/metabolic cell factories prove it is not just a diabetes device; broader allogeneic delivery becomes the long-term option value.

Core answer: for ImmunoShield, realistic “annual consumption” is low-volume, high-value. A serious partner may consume 1 feasibility study, 0–1 co-development package, and 0 platform licenses most years. Strategic platform licenses or acquisitions are episodic, not annual repeat purchases.

Feasibility studies: Likely 2–6 light evaluations per year across enabling technologies, but only 0–2 deep paid studies in a narrow area like encapsulated allogeneic T1D cell therapy.

Platform licenses: Usually 0–1 per year in a specific modality. Pharma may scan many platforms, but they do not license many preclinical platform technologies in the same problem space annually.

Co-development deals: Likely 0–2 per year in cell therapy platform adjacencies.

Encapsulation devices: Preclinical only. Think dozens to hundreds of research units, not recurring commercial device demand.

IND-enabling support: Likely 1–3 active cell therapy programs may need regulatory / translational support in a given year, but only one would be close enough to ImmunoShield’s platform.

Vertex’s acquisition of ViaCyte was a single strategic T1D cell therapy platform consolidation, not an annual repeat purchase; the deal was $320M cash. (Vertex Pharmaceuticals)

Lilly’s Sigilon move also shows episodic strategic consumption: Lilly completed the acquisition to continue encapsulated cell therapy work, including SIG-002 for T1D. (Eli Lilly and Company) BioProcess International reported the acquisition economics as $34.6M upfront with potential total payout up to $309.6M tied to regulatory and development milestones. (BioProcess International)

AstraZeneca’s EsoBiotec acquisition is another one-off strategic platform move: up to $1B total, including $425M upfront and $575M contingent on development/regulatory milestones. (AstraZeneca)

For a large pharma sponsor, assume:

1 serious ImmunoShield-relevant partner action per year is good; 2 is excellent; 3+ is unlikely.

Feasibility studies: Likely 1–3/year, depending on funding and how acute the delivery problem is.

Platform licenses: Usually 0–1 every 2–4 years. A biotech cannot afford to churn core platform architecture frequently.

Co-development deals: Likely 0–1/year. If they adopt ImmunoShield, it becomes a major program choice.

Encapsulation devices: Study-scale only: tens to hundreds for in vitro / small-animal work; small batches for large-animal or IND-enabling studies.

IND-enabling support: Usually focused on one lead program. A biotech may not have multiple simultaneous IND-enabling cell therapy programs.

ImmunoShield’s own deck frames next milestones around platform data package, partner engagement, financing, pipeline progress, and regulatory meetings, not high-volume device consumption. It also states that small-animal models are complete and that the lead program is moving toward large-animal / IND-enabling work.

Matthew’s outreach email likewise says ImmunoShield is entering NHP studies that will generate IND-enabling data in 2–3 years, initially targeting T1D through a partnering-first business model.

For a biotech partner, assume:

One paid feasibility or co-development relationship is a major annual event, not routine consumption.

Feasibility studies: Likely 2–8 technical evaluations/year, especially if the CDMO is scouting differentiating capabilities for cell therapy manufacturing.

Platform licenses: Likely 0–1/year, usually non-exclusive or field-limited.

Co-development deals: Likely 1–3/year, if framed as process-development capability rather than therapeutic ownership.

Encapsulation devices: Could consume more units than pharma/biotech in development settings: hundreds to low thousands for process optimization, QC, training, and demo runs.

IND-enabling support: Likely 1–4 tech-transfer / process packages per year, depending on customer demand.

ImmunoShield’s deck emphasizes highly scalable cell therapy manufacturing technologies, customer discovery from a CMC lead, and an automated injection-molding system that can embed into advanced cell manufacturing processes. It also notes >350 ARMI service hours across regulatory, commercialization, quality, and manufacturing readiness.

Manufacturing partners may consume the most repeated technical work, but the strategic risk is commoditization:

Good for validation and process fit; dangerous if it turns ImmunoShield into a tool vendor instead of a platform company.

Realistic annual consumption across the full target universe:

5–12 qualified feasibility starts/year if the BD engine is excellent.

But paid, high-quality studies are probably:

2–5/year.

Realistic annual consumption:

0–2/year.

More than that is unlikely before strong large-animal, CMC, and regulatory evidence.

Realistic annual consumption:

1–3/year.

This is the best near-term monetization benchmark.

Do not benchmark this as a commercial unit yet.

Near-term consumption is:

research / preclinical / process-development batches, not market-scale devices.

Realistic annual consumption:

1–3 serious support packages/year, tied to a specific partner program or ImmunoShield’s own lead NHP / regulatory path.

The model should assume:

Low volume, high strategic leverage.

A healthy annual target is not 20 partners buying something.

A healthy annual target is:

• 6–10 qualified partner conversations
• 2–5 paid feasibility / readiness studies
• 1–2 co-development packages
• 0–1 platform license or option-to-license

Large pharma: consumes rarely but pays meaningfully. Biotech: consumes selectively, usually around one lead program. Manufacturing partner: consumes more repeat work, but risks weaker strategic positioning.

Best ImmunoShield benchmark: Aim for 1–2 meaningful partner commitments per year, not dozens of transactions. If the business case requires more than 3 serious co-development or license events annually, the scope or unit definition is probably wrong.

Core answer: ImmunoShield is not being “bought” at one moment. It must survive a long consumption chain where each function asks a different version of the same question:

Does this make our allogeneic cell therapy more viable, or does it create a new development burden?

• Awareness
• Introductory BD conversations
• Scientific review
• Advisor/KOL validation

These are easy because they do not force commitment.

• Feasibility studies
• Cell compatibility tests
• Partner cell sharing
• Early device testing

These require time, cells, and internal champion energy.

• CMC integration
• Regulatory strategy
• Product architecture change
• Surgical workflow
• IND-enabling validation

This is where adoption either becomes real or dies.

The chain does not fail because people dislike ImmunoShield.

It fails when a partner says:

“This is interesting, but adopting it would reset too much of our program.”

So ImmunoShield’s job is to make each step feel like risk reduction, not platform conversion.

Help partners name the problem correctly:

“You do not just have an immune rejection problem. You have a product-format problem.”

Offer a defined package:

Partner-readiness sprint: cell compatibility + encapsulation performance + CMC fit + regulatory implications.

Show exactly where ImmunoShield plugs into the partner process.

This is where “manufacturing fit” becomes believable.

Bring a clear FDA interaction strategy:

• INTERACT logic
• Pre-IND questions
• combination-product rationale
• risk register
• evidence plan

Avoid binary adoption.

Use:

feasibility → option → co-development → license

not:

“buy our platform now.”

Based on the deck, ImmunoShield’s current strongest value is:

• reframing the problem from best cell to better product format
• offering a retrievable macroencapsulation device
• showing manufacturing fit through hydrogel injection molding
• creating a path toward partner readiness
• using T1D as proof beachhead while preserving broader platform upside

The future value depends on:

• large-animal validation
• immune tolerance mechanism and efficacy
• FDA feedback
• partner-specific cell compatibility
• scalable QA/QC
• surgical workflow acceptance
• commercial economics

Matthew’s outreach email is aligned with this: ImmunoShield is entering NHP studies to generate IND-enabling data in 2–3 years and is pursuing a partnering-first model.

The consumption chain is the strategy.

ImmunoShield should not ask, “Who wants our technology?”

It should ask:

At which step does each buyer feel the most pain, and what proof do they need to keep moving one step forward?

Core answer: cell therapy developers are not choosing between “ImmunoShield or nothing.” They are choosing among imperfect ways to make therapeutic cells tolerable, durable, and commercially usable.

The strongest competitors are not just companies.

They are default behaviors:

1. Keep using immunosuppression.
2. Build internally.
3. Wait.
4. Narrow the eligible population.
5. Bet on gene editing.

ImmunoShield’s wedge is strongest where the partner believes:

“We need immune protection, but we do not want irreversible biology, chronic systemic suppression, or a device format that cannot scale or be retrieved.”

That is where ImmunoShield’s combination of protection, retrievability, manufacturing fit, and future immune tolerance becomes strategically distinct.

Important caveat: this is a _strategy matrix_, not a proven clinical superiority claim. “2x better” means meaningfully advantaged on adoption logic, not clinically proven twice as effective.

ImmunoShield’s strongest claim is not one feature. It is the bundle:

protection + oxygen-aware geometry + retrievability + manufacturing fit + future immune tolerance

That bundle supports the strategy: help good allogeneic cells become safer, scalable, partner-ready products.

#Core answer: ImmunoShield’s worst links are not in the story. The story is strong. The weak links are in proof maturity, partner adoption risk, and regulatory/CMC confidence.

The platform can still be attractive, but buyers will not ask, “Is this exciting?” They will ask:

“Does adopting this reduce our risk more than it adds new risk?”

This is the obvious weak link.

They have preclinical evidence and a plan for NHP / IND-enabling studies, but not clinical validation. The deck itself places them on the path from high-risk → de-risk → partnership → acquisition → approved product, not at the end of it.

Likely customer behavior: Large pharma listens, takes the meeting, asks for data, then waits.

Risk: acceptable if the offer is a partner-readiness sprint or option-to-license, not a full platform conversion.

---

Combination product risk is real. A partner may worry that ImmunoShield helps immune protection but complicates the IND.

Likely customer behavior: Regulatory affairs slows or blocks adoption until FDA pathway is clearer.

Risk: only acceptable if ImmunoShield proactively builds:

• INTERACT / Pre-IND question set
• combination-product rationale
• evidence map
• risk register
• CMC / device / cell integration plan

---

The immune tolerance story is potentially powerful, but it is not the near-term proof anchor.

The deck itself separates:

• Lead: spiral macroencapsulation
• Pipeline: immune tolerance

That is the right hierarchy.

Likely customer behavior: Partners discount the tolerance story and evaluate ImmunoShield mainly as an encapsulation / delivery platform.

Risk: acceptable. Do not force the tolerance thesis too early.

---

ImmunoShield claims a strong CMC advantage: hydrogel injection molding, reproducibility, and scalability. But the buyer will want to see how it plugs into _their_ process.

Likely customer behavior: CMC says, “Interesting, but not yet ready for our process.”

Risk: acceptable if ImmunoShield turns “manufacturing fit” into a concrete artifact:

process integration map + release assays + sterility strategy + scale-up plan.

---

A device adds implantation, retrieval, monitoring, and workflow questions. This could be worse than gene editing or cell-infusion approaches.

Likely customer behavior: Clinical stakeholders ask whether the procedure burden narrows adoption.

Risk: acceptable if ImmunoShield can show the device improves safety, reversibility, and eligibility enough to justify the workflow.

Yes — but only with the right sequencing.

The risk is acceptable if ImmunoShield leads with:

macroencapsulation as the near-term de-riskable platform

and treats immune tolerance as:

longer-term differentiation and upside.

The risk becomes unacceptable if ImmunoShield tries to sell the full vision before the evidence supports it.

Frame the weakness openly:

“Our biggest risk is not whether the market needs immune protection. It does. Our risk is proving that our approach integrates cleanly enough into a partner’s cell therapy program to reduce more risk than it adds.”

That kind of candor builds credibility.

So what: ImmunoShield’s differentiators are strong, but the worst links are exactly where pharma buyers are most cautious: clinical proof, regulatory clarity, CMC integration, and surgical workflow.

Now what: turn each weak link into a de-risking artifact:

• clinical proof → NHP / IND-enabling data package
• regulatory maturity → FDA interaction roadmap
• immune tolerance → proof-of-mechanism package
• manufacturing readiness → CMC integration map
• surgical adoption → implantation / retrieval workflow brief

Five-year success case: ImmunoShield is no longer perceived as an interesting preclinical encapsulation company. It is perceived as a partner-ready enabling platform that makes allogeneic cell therapies safer, more scalable, retrievable, and commercially broader.

By year 5, success likely means one of three outcomes:

1. Strategic acquisition / option exercised by a large pharma or cell therapy sponsor.
2. Active co-development / license deal tied to one or more allogeneic cell therapy programs.
3. IND-cleared or early clinical-stage enabling platform with partner-funded development.

An approved product within 5 years is possible but likely aggressive given the current preclinical status and Matthew’s stated 2–3 year IND-enabling data horizon.

The sequence that matters most:

Partner readiness → partner feasibility → NHP / IND-enabling data → FDA clarity → co-development / option-to-license → strategic acquisition or clinical-stage platform.

These happen only after the work is funded, executed, and accepted:

• NHP data readout
• small / large animal study completion
• IND-enabling package completion
• FDA feedback receipt
• development milestone payment
• clinical entry
• eventual approved product

These require active leadership now:

• define first paid partner unit
• build target account list
• secure partner-cell access
• prepare CDA/MTA/LOI templates
• create CMC integration map
• prepare INTERACT questions
• develop BD data room
• turn advisors into warm introductions
• convert interest into signed feasibility / co-development commitments

The future will not happen simply because the data improve.

The data must be shaped into partner decisions.

So the five-year success story depends on two parallel tracks:

1. Evidence track: prove safety, function, protection, retrievability, manufacturability.
2. Adoption track: get partners to test, fund, license, co-develop, or acquire.

Five years from now, success looks like:

A serious cell therapy sponsor has either licensed, co-developed, optioned, or acquired ImmunoShield’s platform because the data and regulatory path show that ImmunoShield makes their allogeneic cell product safer, scalable, retrievable, and more commercially viable.

Top assumption to test first: A2 — paid feasibility / partner-readiness conversion.

Why this one: it is cheap enough to test now and strong enough to change strategy. If serious partners will not sign an LOI, share cells, fund a scoped study, or sponsor internal diligence, then the partner-first model needs to change.

Question tested: Will a credible partner take a concrete step toward adoption?

Design: Approach 8–12 named targets with a specific offer:

“We are inviting a small number of cell-therapy sponsors to evaluate whether ImmunoShield can improve protection, retrievability, manufacturability, and partner readiness for their cells. The first step is a scoped partner-readiness sprint.”

Ask for one of three commitments:

• signed LOI
• cells/data access under CDA/MTA
• paid feasibility sprint

Pass threshold:

• 2+ signed LOIs, or
• 1 paid feasibility sprint, or
• 2 partners agree to provide cells / technical data

Fail threshold:

• partners remain complimentary but refuse LOI, budget, cells, or internal sponsor

Strategic consequence if fail: Do not scale BD. Rework the unit, segment, and proof package.

Score:

• Cost: 9/10
• Time: 9/10
• Validity: 9/10

Question tested: Which unit creates the least friction: feasibility study, co-development package, option-to-license, or wait-for-data?

Design: Interview 15–20 people across:

• external innovation
• CMC
• translational engineering
• diabetes cell therapy
• regulatory / development

At the end, force a choice:

“If you had to recommend one next step internally, which would it be: no action, data-room review, unpaid technical diligence, paid feasibility, co-development, option-to-license?”

Pass threshold:

• 5+ ask for confidential data
• 3+ identify budget owner
• 2+ choose paid feasibility or co-development
• 1+ introduces internal sponsor

Fail threshold:

• most choose “wait for NHP data”
• no one identifies budget or internal owner

Strategic consequence if fail: Shift from partner-first revenue to grant-funded de-risking until NHP / CMC evidence is stronger.

Score:

• Cost: 10/10
• Time: 8/10
• Validity: 7/10

Question tested: Is the proposed feasibility study decision-grade for partners?

Design: Build a 3-page protocol:

• partner cell requirements
• encapsulation method
• viability/function readouts
• immune-protection readouts
• CMC integration outputs
• timeline
• partner obligations
• success criteria

Give it to 5 technical buyers:

• 2 CMC leads
• 2 translational engineers
• 1 regulatory/development lead

Ask:

“If this protocol produced positive results, would it be enough to justify a broader co-development or option discussion?”

Pass threshold:

• 3+ say the protocol is decision-grade
• 2+ request edits tied to their own process
• 1+ asks to review under CDA

Fail threshold:

• they say endpoints are interesting but not adoption-relevant
• CMC/regulatory concerns are unresolved
• they require large-animal data before even scoping feasibility

Strategic consequence if fail: Do not sell feasibility yet. First build CMC/regulatory artifacts.

Score:

• Cost: 7/10
• Time: 7/10
• Validity: 8/10

Run them in sequence:

1. Buyer discovery with forced-choice offer
2. Mini feasibility protocol review
3. LOI / paid sprint close

The decisive question:

Will a serious partner move from “interesting platform” to “we will commit cells, money, or internal sponsorship to test this”?

If not, the strategy should pause partner monetization and focus on de-risking evidence.

Purpose: show which checkpoints actually test the make-or-break assumptions, and which activity risks becoming motion without learning.

Legend: Strong test = directly validates; Partial = supports but does not decide; Weak = mostly indirect; Blank = not tested.

The NHP study may prove science, but it does not prove a partner will fund feasibility, co-development, or licensing.

Needed test: signed LOI, paid feasibility, or partner-funded cell compatibility study.

The platform is compelling in T1D, but partner adoption depends on whether _their_ cells survive, function, and fit.

Needed test: partner feasibility sprint.

“Manufacturing fit” is central to the story, but it needs a concrete process map, release specs, sterility plan, and tech-transfer logic.

Needed test: external CMC audit.

Deal comps are helpful, but they do not prove ImmunoShield can command platform economics.

Needed test: option-to-license feedback from BD / external innovation buyers.

1. Partner feasibility — tests willingness to engage and partner-cell fit.
2. CMC readiness — tests manufacturability, the key adoption gate.
3. FDA meeting — tests regulatory path and partner confidence.
4. NHP study — tests core biological / device proof.
5. Tolerance proof — strengthens longer-term platform upside.

So what: the current plan risks over-testing science and under-testing adoption.

Now what: make every checkpoint answer: “Does this increase the chance a partner funds, licenses, co-develops, or acquires ImmunoShield?”

Purpose: prevent ImmunoShield from moving forward on “promising signals” that do not actually reduce risk.

A checkpoint passes only if it changes behavior.

For ImmunoShield, “interesting,” “promising,” or “keep us posted” should count as ambiguous at best, not progress.

“Before we run this checkpoint, we will define the specific decision it must enable. If it does not produce that decision, we will not treat it as validation.”

Status: pre-meeting working ledger. Source base: ImmunoShield deck + Matthew’s April 2026 outreach email.

Most improved confidence: funding secured, pre-seed ask, NHP funding anchor. Most uncertain: partner conversion, license value, acquisition probability. Most important next test: get 1–2 partners to commit cells, funding, or an LOI for a partner-readiness feasibility sprint.

Let's use the outputs from the prior exercises.

From 6B:

Expected BareBones NPV = $47.8M

From 6C:

Worst-Case NPV = $1.5M

(using midpoint of the $1.3M–$2.0M range)

This is a management/investor choice.

Typical ranges:

For ImmunoShield I would use:

Z = 20%

because:

• preclinical
• platform company
• meaningful technical risk
• meaningful regulatory risk
• meaningful adoption risk

but also:

• non-dilutive funding already secured
• strategic acquisition pathway exists
• large market if thesis proves true

---

Spread
=
Expected NPV − Worst Case NPV

=
$47.8M − $1.5M

=
$46.3M

---

Spread Ratio
=
Spread ÷ Expected NPV

=
$46.3M ÷ $47.8M

=
96.9%

Interpretation:

Almost all value currently comes from assumptions that remain unproven.

This is exactly what we would expect for a preclinical platform company.

---

Maximum Investment
=
Spread × Appetite Factor

=
$46.3M × 20%

=
$9.26M

This means:

If the model is directionally correct, it is rational to invest up to approximately:

$9M

to eliminate the assumptions creating the spread.

Not because ImmunoShield is worth $9M today.

Because there is $46M of uncertainty to remove.

---

This is more important.

We do not fund the whole spread.

We fund the next decision.

The next major milestone appears to be:

Partner-ready platform package:
• NHP progress
• FDA interaction
• CMC readiness
• Partner feasibility

From 5C:

Incremental cost:
~$2M–$4M

Therefore:

Allowable Next Investment
=
Cost to next value inflection
+
15% cushion

$2.0M × 1.15

=
$2.3M

$3.0M × 1.15

=
$3.45M

$4.0M × 1.15

=
$4.6M

---

The next investment should not be justified by:

"more runway"

It should be justified by:

"removing the assumptions that dominate value."

Specifically:

---

If I were sitting on the board, I would frame it this way:

• broader indications
• major commercial team expansion
• aggressive conference spending
• extensive tolerance-platform expansion

• NHP studies
• partner feasibility work
• FDA interactions
• CMC readiness
• option-to-license partner discussions

---

Expected NPV:               $47.8M
Worst Case NPV:             $1.5M

Downside Spread:            $46.3M
Spread Ratio:               96.9%

Max Rational Investment:    ~$9.3M

Allowable Next Investment:
$2.3M – $4.6M

Recommended Target:
~$3.5M

The current $500K pre-seed is probably sufficient only if it unlocks partner-funded or grant-funded progress immediately.

If the objective is to reach a true partner-ready inflection point—including NHP evidence, regulatory clarity, CMC readiness, and at least one meaningful partner commitment—the model suggests the total capital required is closer to:

$3–4M beyond today's position, not $500K alone.

That conclusion is consistent with the cost-cushion analysis, the milestone roadmap, and the assumptions creating most of ImmunoShield's current uncertainty.

Checkpoint outcome assumed: partner-ready inflection is incomplete but promising: macroencapsulation has enough evidence to continue, while partner conversion, CMC readiness, and regulatory clarity remain the gating risks.

Best move:

Lead with macroencapsulation as the de-riskable near-term platform; keep immune tolerance as longer-term upside.

Why: it protects partner readiness. Partners can evaluate protection, retrievability, oxygen transport, and manufacturing fit now without needing to believe the full tolerance thesis.

Best move:

Narrow the immediate story to T1D partner-ready macroencapsulation, not broad allogeneic cell therapy infrastructure.

Why: it makes the next milestone crisper: partner-cell feasibility + NHP progress + CMC package + FDA feedback.

Do not fold. Do not broadly accelerate yet.

The best strategy is:

Partition the platform and redirect the near-term commercial story toward the smallest partner-ready wedge.

Use this as a live facilitation script.

“Before we move forward, I want to make sure we are not accidentally building the plan on numbers that only one person believes.

I’m going to read each assumption aloud. For each one, I’ll ask:

Is anyone uncomfortable with this number, source, range, or confidence level?

If no one objects, we’ll treat silence as endorsement for now. If someone disagrees, we’ll capture the alternate value, source, and next test.”

When someone dissents, capture it like this:

Assumption ID:
Dissenting owner:
Concern:
Alternative value/range:
Alternative source:
Confidence:
What evidence would settle it:
Next test:
Decision impact:

“Anything that received no objection is endorsed for now. Anything with dissent becomes a live assumption, not a settled fact. We’ll prioritize tests based on which assumptions most affect partner readiness, runway, and strategic value.”

Purpose: convert the assumption ledger into decision-ready evidence.

1. Partner target list
2. Feasibility sprint package
3. CMC integration map
4. FDA question set
5. NHP study plan

At the next review, the team should decide:

Do we have enough partner, CMC, regulatory, and NHP clarity to pursue paid partner-readiness sprints — or must we first de-risk internally?